Using Heart Electrical Signals to Study How Well Treatments Prevent Dangerous Heart Rhythms in Active People
Launched by UNIVERSITY OF LEICESTER · Jun 9, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand how certain patterns in heart electrical signals can help identify athletes who may be at risk for dangerous heart rhythms, such as sudden cardiac arrest. The researchers want to see if two specific markers (R2I2 and PERS) can help find athletes at higher risk and if exercise tests can provide the same information as more invasive hospital procedures. Participants will include active individuals aged 18 and older, especially those who regularly exercise for at least three hours a week. Athletes with implanted heart devices like defibrillators or pacemakers will be compared to those without these devices.
If you decide to participate, you can expect to undergo several heart monitoring tests, including ECG recordings while resting and exercising, and a continuous 24-hour ECG. The study is not yet recruiting participants, but it's important to know that you won't be eligible if you're pregnant, have certain heart conditions, or are unable to follow the study's protocols. This research aims to improve how we detect and prevent serious heart issues in athletes, making it a meaningful opportunity for those who qualify.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 and over.
- • Participates in regular physical activity for at least 3 hours or greater weekly.
- • Having Implantable cardioverter defibrillator insitu (cases).
- • Having a cardiac pacemaker (control).
- • Having no cardiac device (control).
- • Sufficient capacity and agreement to participate orally and signed written consent forms.
- • Understanding of written and spoken English language.
- Exclusion Criteria:
- • Pregnancy, as detected by positive urine pregnancy test result.
- • Inability to comply with study protocols.
- • Any iatrogenic cardiac pathology (stents, CABG etc).
- • Unstable ventricular tachycardia (\>30 seconds).
- • Any unstable malignant arrhythmia.
- • Fever or presence of a clinically diagnosed febrile illness
About University Of Leicester
The University of Leicester is a leading research institution in the UK, renowned for its commitment to advancing scientific knowledge and improving healthcare through innovative clinical trials. The university fosters a collaborative environment that integrates diverse disciplines, enabling the development of cutting-edge research initiatives aimed at addressing pressing medical challenges. With a focus on ethical practices and patient-centered outcomes, the University of Leicester is dedicated to enhancing clinical research methodologies and contributing to the advancement of medical sciences, ultimately striving to translate research findings into tangible health benefits for communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leicester, Leicestershire, United Kingdom
Patients applied
Trial Officials
Ghulam André Ng, MBChB, MRCP, Ph.D, FRCP
Study Director
University of Leicester, Leicestershire, United Kingdom
Ghulam André Ng, MBChB, MRCP, Ph.D, FRCP, FHEA
Principal Investigator
University of Leicester, Leicestershire, United Kingdom
Xin Li, PhD, MSc, BSc, FHEA
Principal Investigator
University of Leicester, Leicestershire, United Kingdom
Harshil Dhutia, MBBS, BSC, MRCP, CCDS, MD(RES)
Principal Investigator
Glenfield Hospital, Leicester
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported